13. Skin - guidance

To access BNF Formulary section click on the link under BNF Section/s

To access the Guidance Document click on the highlighted text under the Title column

Use documents past their review date with Caution

BNF Section/s	Title	Issuing Body	Date of Issue	Update Due
13.3.1.4	Abrocitinib	High-Cost Drugs
13.3.1.4	Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis TA814	NICE	Aug 2022
13.3.1.4	Baricitinib	High-Cost Drugs
13.3.1.4	Baricitinib - Baricitinib for treating moderate to severe atopic dermatitis TA681	NICE	Mar 2021	*2024*
13.3.1.4	Deucravacitinib	High-Cost Drugs
13.3.1.4	Deucravacitinib - Deucravacitinib for treating moderate to severe plaque psoriasis	NICE	Jun 2023
13.1	Emollients - Emollient Prescribing Guidance for Adults and Children	Kent & Medway ICB	Oct 2023	*Oct 2025*
13.1	Emollients - Patient Leaflet Emollients and How to Use Them Version 1.0	Kent & Medway ICB	Oct 2023	*Oct 2025*
13.1	Emollients - Position statement on Bath and Shower preparations / additives	Kent & Medway ICB	Oct 2023	*Oct 2025*
13.1	Emollients - Patient Information Leaflet on Bath & Shower Preparations	Kent & Medway ICB	Oct 2023	*Oct 2025*
13.4.	Hyperhidrosis - Hyperhidrosis Treatment Guidance	Kent & Medway PRGC	May 2014	-
13.10	Ingenol mebutate - Ingenol mebutate (Picato) Safety Alert - discontinued due to risk of skin malignancy	MHRA	Feb 2020	-
13. / 13.1/13.1.5	Moisture Damage Medway CCG Only - Prescribing Guidance for Barrier Creams	MCH	Nov 2018	*Nov 2020*
13.3.1.4	Tralokinumab	High-Cost Drugs
13.3.1.4	Upadacitinib	High-Cost Drugs